Stephen Hanauer to Adrenal Cortex Hormones
This is a "connection" page, showing publications Stephen Hanauer has written about Adrenal Cortex Hormones.
Connection Strength
2.375
-
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2023 01; 57(1):150-151.
Score: 0.790
-
Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology. 2003 Sep; 125(3):906-10.
Score: 0.208
-
The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
Score: 0.199
-
Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov; 23(5):429-48.
Score: 0.171
-
Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020 02; 115(2):202-210.
Score: 0.162
-
Treat the patient or treat the disease? Dig Dis. 2012; 30(4):400-3.
Score: 0.096
-
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219.
Score: 0.088
-
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9.
Score: 0.082
-
Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol Suppl. 1990; 175:97-106.
Score: 0.081
-
Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008 Mar; 27 Suppl 1:15-21.
Score: 0.071
-
Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov; 2(11):493.
Score: 0.060
-
Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005 May-Jun; 39(5):390-5.
Score: 0.058
-
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13.
Score: 0.054
-
Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord. 2001; 1(4):169-76.
Score: 0.043
-
Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):297-321.
Score: 0.039
-
Inflammatory bowel disease. N Engl J Med. 1996 Mar 28; 334(13):841-8.
Score: 0.031
-
Medical therapy of ulcerative colitis. Lancet. 1993 Aug 14; 342(8868):412-7.
Score: 0.026
-
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201.
Score: 0.022
-
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
Score: 0.022
-
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86.
Score: 0.016
-
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
Score: 0.016
-
Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21.
Score: 0.014
-
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8.
Score: 0.011
-
Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44.
Score: 0.011
-
Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology. 1983 Dec; 85(6):1313-8.
Score: 0.003